Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
4.87
-0.23 (-4.51%)
At close: Aug 27, 2025, 3:59 PM
4.67
-4.01%
After-hours: Aug 27, 2025, 05:19 PM EDT
Acurx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -2.25M | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M | -3.11M | -3.45M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4M | -1.47M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 410.4K | 443.68K | 538.37K | 466.59K | 1.23M | 1.2M | 1.23M | 833.28K | 806.49K | 899.38K | 812.47K | 824.04K | 716.68K | 949.17K | 760.14K | 3.4M | 2.26M | 327.14K |
Other Working Capital | 205.52K | -397.11K | -53.22K | 211.43K | 62.18K | -14.33K | -310.15K | 188.19K | 1.06M | 70.65K | 952.46K | 537.5K | -86.8K | -155.03K | 366.75K | -1.39M | 1.48M | -316.71K |
Other Non-Cash Items | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -66.5K | 916.76K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 165.31K | -345.98K | -6.98K | 165.19K | 11.05K | 114.83K | -310.15K | 188.19K | 1.06M | 70.65K | 952.46K | 537.5K | -86.8K | -155.03K | 366.75K | -1.39M | 1.48M | -316.71K |
Operating Cash Flow | -1.67M | -2.05M | -2.25M | -2.19M | -2.88M | -3.06M | -4.2M | -2.09M | -1.58M | -1.93M | -1.5M | -2.18M | -1.99M | -1.88M | -1.5M | -2.64M | -329.81K | -547.14K |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2.48M | n/a | n/a | n/a | n/a | 210.2K | 4.62M | 3.54M | 73.00 | n/a | n/a | 3.7M | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 3.09M | 2.99M | 194.55K | 1.59M | 320.21K | 4.51M | 4.62M | n/a | 3.54M | n/a | n/a | 3.7M | n/a | n/a | n/a | n/a | 14.8M | n/a |
Net Cash Flow | 1.42M | 937.17K | -2.06M | -598.29K | -2.56M | 1.45M | 421.86K | -2.09M | 1.97M | -1.93M | -1.5M | 1.52M | -1.99M | -1.88M | -1.5M | -2.64M | 14.47M | -547.14K |
Free Cash Flow | -1.67M | -2.05M | -2.25M | -2.19M | -2.88M | -3.06M | -4.2M | -2.09M | -1.58M | -1.93M | -1.5M | -2.18M | -1.99M | -1.88M | -1.5M | -2.64M | -329.81K | -547.14K |